444 West Lake Street
Suite 1700
Chicago, IL 60606
United States
312 416 8592
https://maiabiotech.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 13
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, CEO & Chairman of the Board of Directors | 529,82k | S.O. | 1970 |
Mr. Jeffrey C. Himmelreich | Head of Finance | 213,17k | S.O. | 1975 |
Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer | 417,33k | S.O. | 1960 |
Linda Moreira | Company Secretary | S.O. | S.O. | S.O. |
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
L’ISS Governance QualityScore de MAIA Biotechnology, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..